98%
921
2 minutes
20
Background: The introduction of novel therapeutics into clinical practice could impact equity in health outcomes.
Methods: This was a retrospective, observational cohort study based on the Get With The Guidelines-Stroke program of the American Heart Association. Two epochs were considered: January 2010 to December 2014 and January 2016 to December 2019. The primary exposure was the availability of endovascular thrombectomy (EVT) at the hospital level defined by the degree of implementation of EVT (>10% change from pre-2015 to post-2015) after balancing key patient and hospital characteristics with overlap weighting. The coprimary end points were (1) the difference in in-hospital mortality for patients from counties with median income >$60 000 versus <$60 000 and (2) the difference in in-hospital mortality between Black and White patients. Secondary end points were differences in in-hospital mortality by sex, insurance status, county-level poverty, and county-level educational attainment. Exploratory end points were differences in ambulatory status at hospital discharge and a composite of in-hospital mortality/discharge to hospice across the above categories.
Results: Of 173 049 patients (median age, 75 years; 53.9% female) potentially eligible for EVT, 39 196 (22.7%) received EVT (7572 [10.0% of potentially eligible patients] between 2010 and 2014 and 31 624 [32.6% of potentially eligible patients] between 2016 and 2019). From 2010 to 2014, 1565 (20.7%) of patients and from 2016 to 2019, 5158 (16.3%) who received EVT died in hospital. Implementation of EVT was associated with decreased disparities in mortality rates for patients from counties with median inflation-adjusted income >$60 000 versus <$60 000 (absolute risk difference, 3.9% [95% CI, 0.53%-7.3%]). Implementation of EVT was not associated with changes in differences in in-hospital mortality by race, sex, county poverty rates, county educational attainment, or insurance status.
Conclusions: Among patients with acute ischemic stroke who were potentially eligible for EVT, the implementation of EVT on a hospital level did not worsen health equity in any dimension (race/ethnicity, sex, or insurance status) and was associated with improvements in socioeconomic equity in acute ischemic stroke mortality.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/STROKEAHA.125.051312 | DOI Listing |
J Am Heart Assoc
September 2025
Division of Experimental Cardiology, Department of Cardiology Erasmus MC University Medical Center Rotterdam The Netherlands.
Background: Despite successful recanalization after endovascular thrombectomy, more than half of patients with acute ischemic stroke with large-vessel occlusions experience an unsatisfactory outcome. Incomplete microvascular reperfusion may contribute to it, but its occurrence remains debated, partly due to clinical observations of hyperperfusion after recanalization. This study investigates the relationship between ischemia duration, infarct development, microclot presence, and cerebral perfusion in a swine model of focal cerebral ischemia and reperfusion.
View Article and Find Full Text PDFJ Neurointerv Surg
September 2025
Department of Neurosurgery, Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.
Background: The ESCAPE-MeVO (Endovascular Treatment to Improve Outcomes for Medium Vessel Occlusions) and DISTAL (Endovascular Therapy plus Best Medical Treatment vs Best Medical Treatment Alone for Medium Vessel Occlusion Stroke) trials failed to demonstrate the superiority of endovascular thrombectomy over best medical management for medium and small vessel occlusions. Potential limitations of these trials include older patient populations, lower presenting National Institutes of Health Stroke Scale (NIHSS) scores, higher rates of premorbid disability, delayed revascularization times, inclusion of both medium and small vessel occlusions, and widespread use of stent retrievers. Here we present M2 occlusion data from the Imperative Trial, evaluating aspiration thrombectomy with the Zoom System.
View Article and Find Full Text PDFJ Nutr Health Aging
September 2025
Department of Neurology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China; Xiamen Clinical Research Center for Cerebrovascular Diseases, Xiamen, China; Xiamen Quality Control Center for Stroke, Xiamen, China; The School of Clinical Medicine, Fujian Medica
Objectives: To evaluate the Laboratory-based Frailty Index (FI-LAB) for predicting mortality following endovascular therapy (EVT) in elderly patients with large vessel occlusion acute ischemic stroke (LVO-AIS).
Methods: This retrospective study enrolled 382 patients aged ≥60 years undergoing EVT. FI-LAB was constructed using 44 preprocedural laboratory parameters.
Vasc Endovascular Surg
September 2025
Luminis Health Anne Arundel Medical Center, Department of Surgery, Annapolis, MD, USA.
A 49-year-old female presented with subacute onset of severe worsening bilateral lower extremity swelling. Bilateral iliac venous thrombus and extensive thrombus of the inferior vena cava with extension to the right atrium and bilateral segmental pulmonary emboli was identified on imaging. She was initiated on therapeutic anticoagulation prior to undergoing percutaneous mechanical thrombectomy with the RevCore TM device (Inari Medical, Irvine, CA) with retrieval of white, relatively well-formed organized clot vs mass.
View Article and Find Full Text PDFJ Intensive Care Med
September 2025
Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
The implementation of endovascular therapy as a treatment for acute ischemic stroke has developed greatly in recent years. The primary trials demonstrated negative to mixed results, and it wasn't until the MR CLEAN trial that thrombectomy was established as a beneficial treatment. Since then, further studies have continued to provide additional data allowing for expansion of patient eligibility to receive such therapy.
View Article and Find Full Text PDF